澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Cellmid

0.056

0.000

成交量：- -

成交額：3,678.25

市值：1,237.60萬

市盈率：-3.29

高：0.056

開：0.056

低：0.056

收：0.056

52周最高：0.056

52周最低：0.056

股本：2.21億

流通股本：1.46億

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.017

每股收益(LYR):-0.024

淨資產收益率：-37.59%

總資產收益率：-14.43%

市淨率：1.19

市盈率(LYR):-2.33

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Cellmid

交易所：

ASX

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.cellmid.com.au

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CDY.AU/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CDY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CDY.AU\",,,,,undefined,":{"symbol":"CDY.AU","market":"AU","secType":"STK","nameCN":"Cellmid","latestPrice":0.056,"timestamp":1772166360410,"preClose":0.056,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"Cellmid","floatShares":146143717,"shares":221000000,"eps":-0.017,"marketStatus":"交易中","change":0,"latestTime":"02-27 15:26:00 AEDT","open":0.056,"high":0.056,"low":0.056,"amount":3678.248032956,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.017,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1772168400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.056,"openAndCloseTimeList":[[1772146800000,1772168400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CDY.AU\",,,,,undefined,":{"symbol":"CDY.AU","floatShares":146143717,"roa":"-14.43%","roe":"-37.59%","lyrEps":-0.023984,"shares":221000000,"dividePrice":0,"high":0.056,"amplitude":0,"preClose":0.056,"low":0.056,"week52Low":0.056,"pbRate":"1.19","week52High":0.056,"institutionHeld":0,"latestPrice":0.056,"eps":-0.017,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.017,"open":0.056,"prevYearClose":0.056,"prevWeekClose":0.056,"prevMonthClose":0.056,"prevQuarterClose":0.056,"fiveDayClose":0.056,"twentyDayClose":0.056,"sixtyDayClose":0.056},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDY.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDY.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.cellmid.com.au","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.0219},{"period":"3month","weight":0.049},{"period":"6month","weight":0.0848},{"period":"1year","weight":0.2118},{"period":"ytd","weight":0.0295}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.4375,"avgChangeRate":0.056986},{"month":2,"riseRate":0.3125,"avgChangeRate":-0.006186},{"month":3,"riseRate":0.466667,"avgChangeRate":0.042147},{"month":4,"riseRate":0.1875,"avgChangeRate":-0.055528},{"month":5,"riseRate":0.25,"avgChangeRate":-0.065543},{"month":6,"riseRate":0.6875,"avgChangeRate":0.098275},{"month":7,"riseRate":0.1875,"avgChangeRate":-0.064999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.000407},{"month":9,"riseRate":0.3125,"avgChangeRate":0.0297},{"month":10,"riseRate":0.1875,"avgChangeRate":-0.024917},{"month":11,"riseRate":0.25,"avgChangeRate":-0.011357},{"month":12,"riseRate":0.375,"avgChangeRate":0.005962}],"exchange":"ASX","name":"Cellmid","nameEN":"Cellmid"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CDY.AU\",market:\"AU\",,,undefined,":null}}